Genie Biotech is a biotechnology company located in the UK, and Lithuania (Europe), that specializes in offering novel bioconjugation platform technologies. Formed in 2018 by research scientists from the Universities of Imperial College London and Oxford, Genie Biotech soon developed its first preclinical-stage site-specific conjugation chemistry (patent pending) offering a Proof-of-Concept/Out-Licensing model to clients looking to explore novel modalities that improve their therapeutic and vaccine pipeline candidates. | At Genie Biotech, we apply our novel bioconjugation techniques to support discovery-phase research and pave the way for the next generation of bioconjugates. Purchase off-the-shelf products for your R&D activities or leverage our bioconjugation expertise, protein production capabilities and comprehensive characterization suite, to identify the right site-specific conjugation solutions for your nanoparticle vaccine, antibody drug conjugate or diagnostic product. In collaboration with you, we’ll help accelerate your transition from R&D to commericial product.
